Summit Therapeutics Inc. Announces Partner to Present Phase III Survival Data

What Happened
Summit Therapeutics Inc. (SMMT) filed a Form 8‑K on September 14, 2026, reporting that its partner Akeso Inc. announced updated data — including overall survival — from the randomized, double‑blind Phase III HARMONi‑2 trial. Akeso will present these data at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer on Tuesday, September 15, 2026. Summit attached Akeso’s September 13, 2026 press release as Exhibit 99.1 to the 8‑K.

Key Details

• Partner: Akeso Inc. announced the presentation; Summit is reporting the partner’s announcement via Form 8‑K (Item 8.01).
• Trial: HARMONi‑2 — randomized, double‑blind Phase III study.
• Data to be presented: Updated results including overall survival.
• Presentation date and venue: September 15, 2026 at IASLC World Conference on Lung Cancer (WCLC) 2026.
• Filing: Summit filed the 8‑K on September 14, 2026 and attached the press release dated September 13, 2026 as Exhibit 99.1.

Why It Matters
Updated Phase III data, especially overall survival, are material clinical readouts that can affect the development path and perceived value of the drug candidate being studied. For investors, the presentation timing (Sept 15, 2026) is a near‑term event to watch for potential data that could influence Summit’s outlook, partner progress, and market reaction. The 8‑K does not disclose the results themselves; it reports Akeso’s announcement and the planned presentation.